search

Active clinical trials for "Venous Thrombosis"

Results 111-120 of 679

Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT...

Deep Vein Thrombosis

A single centre, single-arm study to evaluate safety and efficacy of microplasmin administration via the Trellis-8 Infusion System in patients with acute iliofemoral DVT

Terminated18 enrollment criteria

ClotTriever Outcomes (CLOUT) Registry

Deep Vein Thrombosis LegDVT2 more

Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.

Active10 enrollment criteria

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting...

Deep Vein Thrombosis LegStroke (in Patients With Atrial Fibrillation)

A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns.

Terminated31 enrollment criteria

Post-Market Clinical Follow-up Study With ASPIREX®S to Assess the Safety and Effectiveness in the...

Deep Vein ThrombosisBypass Complication2 more

The ASPIREX®S Endovascular System is a rotating and aspirating catheter system. It is intended to be used for the percutaneous transluminal removal of fresh thrombotic or thromboembolic material from native blood vessels (or vessels fitted with stents, stent grafts or native or artificial bypasses) outside the cardiopulmonary, coronary and cerebral circulations. CAPTUREX® , a catheter with a filter basket, is intended to be used for the filtering of emboli from blood vessels during potentially embolizing procedures on the patient. ASPIREX®S and CAPTUREX® are CE-marked (Class III) medical devices. In this study the effectiveness and safety in the removal of thrombi in veins is assessed under real life setting.

Active19 enrollment criteria

The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses

Venous Thrombosis

To study the safety and efficacy of drug coated stents for the treatment of venous occlusions and stenoses in the lower extremity. The use of the device for the treatment of peripheral arterial disease is approved by the FDA, however, the use of the device in venous occlusions and stenoses, although performed by some practitioners, has not yet been studied in detail.

Terminated11 enrollment criteria

EVENT: Hydrotherapy and Deep Venous Thrombosis

PainDeep Venous Thrombosis

The main objective of this study is to demonstrate that hydrotherapy in a specific place can reduce the risk of post-thrombotic syndrome.

Terminated15 enrollment criteria

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

COVID-19Pulmonary Embolism1 more

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

Terminated20 enrollment criteria

Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study

Coronary Heart DiseaseType 2 Diabetes1 more

P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally Implemented in Finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type 2 diabetes) and one feature (venous thromboembolism). The hypothesis of the study is that 1) combining genetic and metabolic risk with traditional risk factors adds value to the personal risk assessment of these diseases, 2) such risk information can be provided to individuals using a web based user portal in an easily understandable and useful format, and 3) receiving genetic and metabolomic risk information has an effect on the health of the study participants. The study is a continuation of FinHealth 2017 -study, which involved more than 7,000 Finns from around the country. The participants of FinHealth were invited to participate in P5.fi -study. The new research utilises information, samples, and measurements obtained in the FinHealth Study. Prospective clinical significance of selected genetic and metabolomic risk scores will be studied in 30.000 Finnish individuals. The study will analyze the genetic and metabolomic profile of the P5.fi participants and develop and test a protocol for returning them health related risk information. The impact of the intervention will by followed up by questionnaires and national health registers for five years.

Active2 enrollment criteria

Calf Deep Vein Thrombosis Treatment Trial

Deep Vein Thrombosis

The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or recurring DVTs.

Terminated34 enrollment criteria

Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF...

Pulmonary EmbolismDeep Vein Thrombosis

The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF. The study will compare the method of Crux VCF deployment using the LUMIFI with Crux VCF System (IVUS guidance) with the historical results of the Crux VCF System (fluoroscopic guidance). The study will include enrollment into a roll in phase consisting of 2 study subjects per site prior to enrollment into the primary treatment phase for primary analyses. The purpose of the roll in phase is to assure compliance with site training on the use of the investigational device and protocol workflow.

Terminated25 enrollment criteria
1...111213...68

Need Help? Contact our team!


We'll reach out to this number within 24 hrs